
**PROFIT GUIDANCE FOR THE GROUP'S UNAUDITED FINANCIAL RESULTS
FOR SECOND HALF AND FINANCIAL YEAR ENDED 31 DECEMBER 2021**

The Board of Directors (the “**Board**”) of Pharmesis International Ltd. (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) wishes to announce that after preliminary assessment of the Group’s unaudited financial results, the Board would like to inform the shareholders and investors that the Group is expected to report a net profit for the unaudited financial results for the second half (“**2HFY21**”) and financial year ended 31 December 2021 (“**FY2021**”) as compared to a net loss for the corresponding periods for the second half (“**2HFY20**”) and financial year ended 31 December 2020 (“**FY2020**”).

The expected net profit was mainly attributed to higher other income and lower costs in the 2HFY21 & FY2021.

Further details of the Group’s financial performance will be disclosed when the Company announces its unaudited financial results for 2HFY21 & FY2021.

The Board wishes to advise its shareholders and investors to exercise caution when dealing with the shares of the Company. Shareholders and investors should consult with their stock brokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions that they should take.

BY ORDER OF THE BOARD

Wu Xuedan
Executive Director and Chief Executive Officer
21 February 2022